Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 14/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.60 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6138260 | 0.82 | OPRL1 (0.78) | OPRL1OPRM1KDM1AOPRK1SLC6A4 | |
| SCHEMBL4352487 | 0.82 | OPRL1 (0.60) | OPRL1OPRM1KDM1AOPRK1SLC6A4 | |
| SCHEMBL28386466 | 0.82 | KDM1A (0.40) | OPRL1OPRM1KDM1ASLC6A4TACR1 | |
| SCHEMBL5167763 | 0.80 | OPRM1 (0.54) | OPRL1OPRM1KDM1AOPRK1SLC6A4 | |
| SCHEMBL3411324 | 0.75 | OPRL1 (1.00) | OPRL1OPRM1KDM1AOPRK1SLC6A4 | |
| SCHEMBL3413567 | 0.74 | OPRL1 (0.61) | OPRL1OPRM1KDM1AOPRK1SLC6A4 | |
| SCHEMBL3406916 | 0.73 | OPRL1 (0.64) | OPRL1OPRM1KDM1AOPRK1SLC6A4 | |
| SCHEMBL3408991 | 0.73 | OPRL1 (1.00) | OPRL1OPRM1OPRK1 | |
| SCHEMBL3409102 | 0.71 | OPRL1 (0.61) | OPRL1OPRM1KDM1AOPRK1SLC6A4 | |
| SCHEMBL4355485 | 0.70 | OPRM1 (0.49) | OPRL1OPRM1SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580386-B2 | Substituted 4-aminocyclohexane derivatives | GRÜNENTHAL (DE) | 2017-02-28 | — | — | US | disclosed |
| US-9403767-B2 | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| US-20140357634-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2014-12-04 | — | — | US | disclosed |
| US-8835689-B2 | Substituted 4-aminocyclohexane derivatives | Grünenthal GmbH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-20130197095-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20120202810-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2012-08-09 | — | — | US | disclosed |
| US-20090247530-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357634-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | OPRL1 1/4885OPRM1 4/4885KDM1A 2884/4885 |
| US-20090247530-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | OPRL1 1/4885OPRM1 4/4885KDM1A 2884/4885 |
| US-20120202810-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | OPRL1 1/4885OPRM1 4/4885KDM1A 2884/4885 |
| US-20130197095-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | OPRL1 1/4885OPRM1 4/4885KDM1A 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.